Supplementary Table S1. Patient characteristics according to osimertinib response groups by 6-month PFS

Characteristics	Unfavorable group (PFS <6 mo) (n=23)	Favorable group (PFS ≥6 mo) (n=38)	p-value
Age at diagnosis (mean), yr	62.4±13.9	63.8±10.7	0.655
Sex			
Female	13 (34)	25 (66)	0.469
Male	10 (43)	13 (57)	
Performance at osimertinib initiation			
ECOG 0–1	14 (33)	29 (67)	0.200
ECOG 2–4	9 (50)	9 (50)	
Smoking status			
Never smoker	12 (31)	27 (69)	0.137
Ever smoker	11 (50)	11 (50)	
Baseline NLR at osimertinib initiation	5.8±3.9	3.5±2.3	0.016
Stage at osimertinib initiation			
IVA	6 (35)	11 (65)	0.809
IVB	17 (39)	27 (61)	
CNS metastasis at osimertinib initiation	10 (42)	14 (58)	0.607
EGFR co-mutation with T790M			
Exon 19 deletion	17 (42)	23 (58)	0.286
Exon 21 L858R/L861Q	6 (29)	15 (71)	
Previous EGFR-TKI			0.106
First-generation (gefitinib/erlotinib)	13 (31)	29 (69)	
Second-generation (afatinib)	10 (53)	9 (47)	
PFS of previous EGFR-TKI, mo			0.204
<10	11 (48)	12 (52)	
≥10	12 (32)	26 (68)	
Treatment line of osimertinib			0.488
Second line	13 (42)	18 (58)	
≥Third line (3–8)	10 (33)	20 (67)	
Response to osimertinib			<0.001
PR	7 (18)	32 (82)	
SD/PD	16 (73)	6 (27)	
Median PFS of previous EGFR-TKI (95% CI), mo	10.1 (7.3–12.9)	13.6 (9.6–17.6)	0.114
Median OS after osimertinib (95% CI), mo	5.7 (3.9–7.5)	21.6 (14.6–28.6)	<0.001

PFS: progression-free survival; ECOG: Eastern Cooperative Oncology Group; NLR: neutrophil-tolymphocyte ratios; CNS: central nervous system; EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitors; PR: partial response; SD: stable disease; PD: progressive disease; OS: overall survival.